Physician profile
Daniel J Dodson
NPI 1033310271
$3,205.99
in general payments reported to CMS, 2019-2025
18 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $123 · 2021: $323 · 2022: $524 · 2023: $568 · 2024: $721 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $463.53 | 2020-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Abbvie INC. | $446.36 | 2022-2025 | Durysta |
| Beaver-Visitec International, INC. | $426.19 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $302.76 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Rxsight INC | $264.67 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $252.90 | 2019-2025 | Idosetr, Idose |
| Johnson & Johnson Surgical Vision, INC. | $210.28 | 2019-2024 | Catalys System |
| Tarsus Pharmaceuticals, INC. | $204.54 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $189.98 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $94.87 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $79.72 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $70.61 | 2021 | |
| Ocular Therapeutix, INC. | $60.89 | 2024 | Dextenza |
| Harrow Eye, LLC | $43.31 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.43 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $23.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.49 | 2022 | |
| Coopervision INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.